The global telmisartan market was valued at $3,453 million in 2019, and is projected to reach $4,258 million by 2027, registering a CAGR of 3.4% from 2020 to 2027. The growth of the global telmisartan ...
Catch this week’s top auto updates! New launches from Mahindra, Mercedes, MG, Honda and Ducati, price updates, EV buzz and ...
Indian equity indices ended strong on Friday, with the NIFTY closing at 23,350.40, up 159.75 points (0.69%), while the Sensex ...
The approval covers Apalutamide tablets of 60 mg strength, the company said in a regulatory filing. The drug will be ...
Zydus Lifesciences rose 3% to an intra-day high of Rs 930 after the company received approval from the US FDA to manufacture ...
As per the IQVIA MAT January 2025 data, apalutamide tablets registered annual sales of $1099.80 million in the United States markets.
The rise in the Zydus Lifesciences shares came after the company received final approval from the United States Food and Drug ...
Zydus Lifesciences said that it has received final approval from the United States Food and Drug Administration (US FDA) to manufacture Apalutamide tablets, 60 mg.
On March 18, post-market hours, Zydus Lifesciences announced that it has received approval from the United States Food & Drug ...
The positive trends at GIFT Nifty futures indicate a gap-up opening for Indian equity benchmarks Sensex and Nifty.
Zydus Lifesciences shares rose 8.34 per cent on March 19, touching an intraday high of Rs 910.30 at 1:00 PM when the company ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback